Prostate-specific antigen in the early detection of prostate cancer

Throughout Canada, the United States and much of Europe, prostate-specific antigen (PSA) screening for prostate cancer has proliferated over the past 2 decades, leading to dramatic increases in detection rates of prostate cancer. Although it has unquestionably led to increased detection of cancer and a migration to lower-stage and -volume tumours, it is still unknown whether PSA screening significantly reduces mortality from prostate cancer. Often thought to be dichotomous (i.e., either normal or elevated), PSA measurements actually reflect cancer risk, with the risks of cancer and of aggressive cancer increasing with the level of PSA. The recently developed risk calculator from the Prostate Cancer Prevention Trial, which integrates family history of prostate cancer, digital rectal examination findings, PSA test result, age, ethnicity, and history of a prior prostate biopsy with a negative result, allows clinicians to assess a patient's individual risk of cancer. This risk should be examined in the context of a patient's life expectancy and comorbidity as well as his concern about the possibility of prostate cancer. The terms “normal” and “elevated” as descriptors of PSA results should be abandoned.

[1]  M. Roobol,et al.  Screening for prostate cancer without digital rectal examination and transrectal ultrasound: Results after four years in the European Randomized Study of Screening for Prostate Cancer (ERSPC), Rotterdam , 2006, The Prostate.

[2]  C. Brendler,et al.  Characterizing prostatic adenocarcinomas in men with a serum prostate specific antigen level of <4.0 ng/mL , 2004, BJU international.

[3]  W. Catalona,et al.  Measurement of prostate-specific antigen in serum as a screening test for prostate cancer. , 1991, The New England journal of medicine.

[4]  I. Thompson,et al.  Adenocarcinoma of the prostate: results of routine urological screening. , 1984, The Journal of urology.

[5]  Fritz H. Schröder,et al.  Evaluation of the Digital Rectal Examination as a Screening Test for Prostate Cancer , 1998 .

[6]  A W Partin,et al.  Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: a prospective multicenter clinical trial. , 1998, JAMA.

[7]  J. Goméz,et al.  Serum prostate specific antigen as pre-screening test for prostate cancer. , 1992, The Journal of urology.

[8]  Javier Hernandez,et al.  External validation of the Prostate Cancer Prevention Trial risk calculator in a screened population. , 2006, Urology.

[9]  F. Saad,et al.  uPM3, a new molecular urine test for the detection of prostate cancer. , 2004, Urology.

[10]  Hugh H. Young,et al.  The early diagnosis and radical cure of carcinoma of the prostate. Being a study of 40 cases and presentation of a radical operation which was carried out in four cases , 2002 .

[11]  E. Crawford,et al.  Prostate Cancer Awareness Week, 1992: a summary of key findings. , 1993, Clinical and investigative medicine. Medecine clinique et experimentale.

[12]  M. Gleave,et al.  Prostate specific antigen: an updated review. , 2003, The Canadian journal of urology.

[13]  T. Stamey,et al.  Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate. , 1988, The New England journal of medicine.

[14]  M. Barry Early detection and aggressive treatment of prostate cancer: groping in the dark. , 2000, Journal of general internal medicine.

[15]  G. Haas,et al.  The frequency of carcinoma and intraepithelial neoplasia of the prostate in young male patients. , 1993, The Journal of urology.

[16]  J. Crowley,et al.  Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter. , 2004, The New England journal of medicine.

[17]  W. Catalona,et al.  Detection of organ-confined prostate cancer is increased through prostate-specific antigen-based screening. , 1993, JAMA.

[18]  D. Ornstein,et al.  Prostate cancer detection in men with serum PSA concentrations of 2.6 to 4.0 ng/mL and benign prostate examination. Enhancement of specificity with free PSA measurements. , 1997, JAMA.

[19]  R. Tarone,et al.  Implications of stage-specific survival rates in assessing recent declines in prostate cancer mortality rates. , 2000, Epidemiology.

[20]  I Mehdi,et al.  Early detection of prostate cancer. , 1998, JPMA. The Journal of the Pakistan Medical Association.

[21]  M. Barry Early detection and aggressive treatment of prostate cancer , 2000, Journal of General Internal Medicine.

[22]  Igor Sartori,et al.  Detection of Organ-Confined Prostate Cancer Is Increased Through Prostate- Specific Antigen-Based Screening: , 1994 .

[23]  Ian M Thompson,et al.  Operating characteristics of prostate-specific antigen in men with an initial PSA level of 3.0 ng/ml or lower. , 2005, JAMA.

[24]  L. Hirsch Competing interests: none declared. , 2006 .

[25]  E. Deantoni,et al.  Eight years of "Prostate cancer awareness week" , 1997, Cancer.

[26]  J. Onysko,et al.  Lifetime and Recent Prostate Specific Antigen (PSA) Screening of Men for Prostate Cancer in Canada , 2006, Canadian journal of public health = Revue canadienne de sante publique.

[27]  P. Scardino,et al.  Early detection of prostate cancer. , 1989, The Urologic clinics of North America.

[28]  T. Tammela,et al.  The European Randomized Study of Screening for Prostate Cancer (ERSPC). , 2010, British journal of urology.

[29]  W W Holland,et al.  Validation of screening procedures. , 1971, British medical bulletin.

[30]  P. Schellhammer,et al.  Serum protein fingerprinting coupled with a pattern-matching algorithm distinguishes prostate cancer from benign prostate hyperplasia and healthy men. , 2002, Cancer research.

[31]  J. Gohagan,et al.  Prostate Cancer Screening in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial: findings from the initial screening round of a randomized trial. , 2005, Journal of the National Cancer Institute.

[32]  I. Thompson,et al.  Digital rectal examination and carcinoma of the prostate. , 1991, The Urologic clinics of North America.

[33]  M. Kattan,et al.  Comparisons of nomograms and urologists' predictions in prostate cancer. , 2002, Seminars in urologic oncology.

[34]  Michael M Lieber,et al.  The influence of finasteride on the development of prostate cancer. , 2003, The New England journal of medicine.

[35]  P. Carroll,et al.  Operating characteristics of prostate-specific antigen in men with an initial PSA level of 3.0 ng/ml or lower , 2005 .

[36]  J. Oesterling,et al.  Age- and race-specific reference ranges for prostate-specific antigen from a large community-based study. , 1996, Urology.

[37]  R A Greenes,et al.  Assessment of diagnostic tests when disease verification is subject to selection bias. , 1983, Biometrics.

[38]  P. Boyle,et al.  Serum prostate-specific antigen as a predictor of prostate volume in men with benign prostatic hyperplasia. , 1999, Urology.

[39]  Michael J Barry,et al.  Natural experiment examining impact of aggressive screening and treatment on prostate cancer mortality in two fixed cohorts from Seattle area and Connecticut , 2002, BMJ : British Medical Journal.

[40]  D. Troyer,et al.  Prognostic features in men who died of prostate cancer. , 2005, The Journal of urology.

[41]  Ja Wilson,et al.  Principles and practice of screening for disease , 1968 .

[42]  M. Terris,et al.  Random systematic versus directed ultrasound guided transrectal core biopsies of the prostate. , 1989, The Journal of urology.

[43]  J. Feightner The early detection and treatment of prostate cancer: the perspective of the Canadian Task Force on the Periodic Health Examination. , 1994, The Journal of urology.

[44]  Shawna L. Mercer,et al.  Prostate cancer screening in the midst of controversy: Canadian men's knowledge, beliefs, utilization, and future intentions. , 1997, Canadian journal of public health = Revue canadienne de sante publique.

[45]  Amit Patel,et al.  Prostate cancer detection with office based saturation biopsy in a repeat biopsy population. , 2004, The Journal of urology.

[46]  J. Williams,et al.  Prostate-specific antigen testing in Ontario: reasons for testing patients without diagnosed prostate cancer. , 1999, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.

[47]  Ziding Feng,et al.  Assessing prostate cancer risk: results from the Prostate Cancer Prevention Trial. , 2006, Journal of the National Cancer Institute.

[48]  P. Walsh,et al.  Radical prostatectomy versus watchful waiting in early prostate cancer. , 2005, The Journal of urology.

[49]  D. Altman,et al.  Diagnostic tests 4: likelihood ratios , 2004, BMJ : British Medical Journal.

[50]  P. Guinan,et al.  An evaluation of prostate specific antigen in prostatic cancer. , 1987, The Journal of urology.

[51]  L. Kiemeney,et al.  DD3(PCA3), a very sensitive and specific marker to detect prostate tumors. , 2002, Cancer research.

[52]  Jerome P. Richie,et al.  Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: a prospective multicenter clinical trial. , 1998, JAMA.